Search results for "Histocompatibility Testing"

showing 10 items of 28 documents

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term foll…

2010

Background Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. Design and Methods The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen w…

AdultMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentFollicular lymphomaHematopoietic stem cell transplantationGastroenterologyreduced intensity conditioningfollicular lymphomaallogeneic stem cell transplantationInternal medicinemedicinegraft-versus-host diseaseHumansTransplantation HomologousLymphoma FollicularSurvival ratebusiness.industryHistocompatibility TestingSiblingsHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseSurgeryFludarabineSurvival RateTransplantationTreatment OutcomeGraft-versus-host diseaseFemaleOriginal ArticleTransplantation ConditioningbusinessProgressive diseaseFollow-Up Studiesmedicine.drugHLA identical sibling donor
researchProduct

Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals.

1997

Activation-induced apoptosis is one of the primary control mechanisms for the negative selection of an immune response, leading to maintenance of immune homeostasis and selective T cell deletion. The interaction between the surface molecule Fas and its ligand (FasL) has been proposed as a primary mechanism initiating T cell apoptosis. The T cell receptor modulates the expression and function of these molecules. Defects in the Fas/FasL apoptosis pathway have been shown to result in autoimmune disease in humans and in murine models. Because subjects carrying the HLA-B8, DR3 haplotype show a number of immune dysfunctions, including membrano-proliferative glomerulonephritis, systemic lupus eryt…

CD3 ComplexT cellCD8 AntigensT-LymphocytesImmunologyAntigens CD19Lipopolysaccharide ReceptorsApoptosisBiologyFas ligandHLA-B8 AntigenImmune systemHLA-DR3 AntigenmedicineImmunology and AllergyCytotoxic T cellHumansfas ReceptorAutoimmune diseaseB-LymphocytesHistocompatibility TestingT-cell receptorGeneral Medicinemedicine.diseaseFas receptorFlow Cytometrymedicine.anatomical_structureApoptosisImmunologyCD4 AntigensCancer researchHuman immunology
researchProduct

Advances in haploidentical stem cell transplantation for hematologic malignancies

2016

One of the most important advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the use of alternative donors and cell sources, such as haploidentical transplants (haplo-HSCT) from family donors. Several approaches have been developed to overcome the challenging bidirectional alloreactivity. We discuss these approaches, including ex vivo T-cell-depleted grafts with megadose of CD34(+) cells, not requiring immunosuppression after allogeneic transplantation for graft-versus-host disease (GVHD) prophylaxis, and other strategies using unmanipulated T-cell-replete grafts with intensive immunosuppression or post-transplantation cyclophosphamide to minimize the GVHD. We als…

Cancer ResearchAllogeneic transplantationmedicine.medical_treatmentGraft vs Host DiseaseContext (language use)Hematopoietic stem cell transplantationT-Lymphocytes RegulatoryLymphocyte DepletionDonor Selection03 medical and health sciences0302 clinical medicineReceptors KIRHLA AntigensmedicineHumansCyclophosphamideDonor selectionbusiness.industryHistocompatibility TestingHematopoietic Stem Cell TransplantationImmunosuppressionHematologyAllograftsTransplantationTreatment Outcomesurgical procedures operativeClinical Trials Phase III as TopicOncologyHematologic Neoplasms030220 oncology & carcinogenesisTransplantation HaploidenticalImmunologyStem cellUnrelated DonorsbusinessImmunosuppressive AgentsEx vivo030215 immunologyLeukemia & Lymphoma
researchProduct

Analysis of TCR Vbeta repertoire and cytokine gene expression in patients with idiopathic dilated cardiomyopathy

2001

Although the etiopathogenesis of idiopathic dilated cardiomyopathy (IDC) is still unclear, it is widely accepted that a complex interplay between viral infections and immune mechanisms is the basis of disease genesis. Previously, we showed that heart-infiltrating T cells of patients suffering from acute, fulminant Coxsackie virus B3+-IDC shared a preferential usage of three variable gene segments of the T cell receptor beta chain-(TCR-Vbeta) encoding families Vbeta3, 7 and 13.1. This indicated the possible presence of a superantigen-driven immune response. Here, we further investigated the IDC immunological scenario by analysing different phenotypes of heart-infiltrating cells: TCR repertoi…

Cardiomyopathy DilatedInterleukin 2MyocarditisCD8 AntigensReceptors Antigen T-Cell alpha-betaT cellImmunologyCardiomyopathyGene Expressionchemical and pharmacologic phenomenaPicornaviridaeBiologyHLA-DQ alpha-ChainsImmunoenzyme TechniquesInterferon-gammaImmune systemAntigenHLA-DQ AntigensIdiopathic dilated cardiomyopathymedicineHLA-DQ beta-ChainsHumansImmunology and AllergyRNA MessengerAntigens ViralInterleukin-6Reverse Transcriptase Polymerase Chain ReactionHistocompatibility TestingMyocardiumIDC cytokines immune mechanismsmedicine.diseaseEnterovirus B HumanMyocarditismedicine.anatomical_structureCD4 AntigensImmunologyLeukocytes MononuclearCytokinesInterleukin-2Interleukin-4CD8Interleukin-1medicine.drug
researchProduct

Anti-HLA immunization of patients qualified for lung transplantation – Single center study

2021

For lung transplantation, the presence of donor-specific anti-HLA antibodies (DSA) is an important factor of antibody-mediated rejection (AMR) in its hyperacute, acute or chronic form during long-term follow up. The aim of the study was to assess the allosensitization of Polish patients qualified for a lung transplantation in our center. A retrospective study of 161 potential lung allograft recipients, also of 31 patients transplanted in the Uni-versity Hospital of Gdansk, between June 2018 and December 2020 were performed. 121 potential recipients were thoroughly tested for immunization status before eventual lung transplantation. SAB-testing, PRA-CDC and vPRA assessment, and HLA typing we…

Graft RejectionAnti-HLA sensitizationTransplantationHistocompatibility TestingImmunologyKidney TransplantationTransplant immunologyHLA AntigensIsoantibodiesHumansImmunology and AllergyImmunizationLung TransplantationRetrospective StudiesTransplant Immunology
researchProduct

14th International HLA and Immunogenetics Workshop: Report on the Prospective Chronic Rejection Project

2007

An international collaborative study of 45 transplant centers was undertaken at the 14th International HLA (human leukocyte antigen) and Immunogenetics Workshop to see if HLA antibodies detected posttransplant are predictive of chronic graft failure. With the newly developed assay, MICA (major histocompatibility complex class I-related chain A) antibodies were also measured and their effect analyzed. Total of 5219 sera from patients who were more than 6 months posttransplant with functioning graft were tested for HLA antibodies by enzyme-linked immunosorbent assay, flow cytometry, or Luminex. HLA antibodies were found in 27.2% of kidney patients, 23.6% in the liver, 52.7% in the heart, and …

Graft RejectionMICA antibodyImmunologyHuman leukocyte antigenHistocompatibility TestingImmunogeneticsMajor histocompatibility complexBiochemistryimmunogenetics workshopchronic rejectionHLA AntigensTransplantation ImmunologyImmunogeneticsGeneticsmedicineHumansImmunology and AllergyHLA antibodyKidneyLungbiologybusiness.industryHistocompatibility TestingGraft SurvivalHistocompatibility Antigens Class IPanel reactive antibodymulti-center studyGeneral MedicineKidney Transplantationmedicine.anatomical_structureChronic DiseaseImmunologybiology.proteinHeart TransplantationAntibodybusinessTissue Antigens
researchProduct

Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell–engrafted NOD/SCID/IL-2Rγcnull mice

2013

Current strategies in cellular immunotherapy of cancer and viral infections include the adoptive transfer of T cell receptor (TCR) and chimeric antigen receptor engineered T cells. When using transient RNA expression systems in clinical studies, multiple infusions with receptor-redirected T cells appear necessary. However, in allogeneic hematopoietic stem-cell transplantation, repeated transfer of donor-derived T cells increases the risk of alloreactive graft-versus-host disease. We investigated naive-derived (T N ), memory-derived (T M ), and Epstein Barr virus-specific (T EBV ) CD8 + T cell subsets for alloreactivity upon redirection with RNA encoding a cytomegalovirus-specific model TCR.…

Herpesvirus 4 HumanCancer ResearchT-LymphocytesT cellAntigens CD34Mice SCIDStreptamerCD8-Positive T-LymphocytesBiologyImmunotherapy AdoptiveMiceInterleukin 21GeneticsmedicineAnimalsHumansTransplantation HomologousCytotoxic T cellIL-2 receptorAntigen-presenting cellMolecular BiologyInterleukin 3Histocompatibility TestingHematopoietic Stem Cell TransplantationCell BiologyHematologyNatural killer T cellmedicine.anatomical_structureImmunologyCancer researchImmunologic MemoryInterleukin Receptor Common gamma SubunitExperimental Hematology
researchProduct

Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: Correlation with graft survival

2017

We reported previously on the widespread occurrence of anti-HLA alloantibodies of the IgA isotype (anti-HLA IgA) in the sera of solid-organ re-transplantation (re-tx) candidates (Arnold et al., ). Specifically focussing on kidney re-tx patients, we now extended our earlier findings by examining the impact of the presence and donor specificity of anti-HLA IgA on graft survival. We observed frequent concurrence of anti-HLA IgA and anti-HLA IgG in 27% of our multicenter collective of 694 kidney re-tx patients. This subgroup displayed significantly reduced graft survival as evidenced by the median time to first dialysis after transplantation (TTD 77 months) compared to patients carrying either …

Male0301 basic medicinemedicine.medical_treatmentMedizinHistocompatibility Testing030230 surgery0302 clinical medicineAntibody SpecificityHLA AntigensIsoantibodiesMedicineChildGenetics (clinical)Aged 80 and overKidneybiologyGraft SurvivalGeneral MedicineMiddle AgedPrognosisIsotypemedicine.anatomical_structureChild PreschoolRetreatmentFemaleAntibodyAdultAdolescentImmunologyHuman leukocyte antigenYoung Adult03 medical and health sciencesGeneticsHumansMolecular BiologyAllelesDialysisAgedbusiness.industryOrgan TransplantationKidney TransplantationTransplant RecipientsImmunoglobulin ATransplantation030104 developmental biologyImmunoglobulin GImmunologybiology.proteinGraft survivalbusinessInternational Journal of Immunogenetics
researchProduct

Association between the HLA-DR alleles and longevity: a study in Sardinian population

2003

Human longevity may be correlated with optimal functioning of the immune system, suggesting that genetic determinants of longevity also resides in those polymorphisms for the immune system genes that regulate immune responses as histocompatibility (HLA) antigens. However, conflicting results have been obtained. Some well planned and designed association studies performed in Caucasians suggest that longevity is associated with positive selection of alleles (i.e. HLA-DR11) or haplotypes (i.e. HLA-B8,DR3) that confer resistance to infectious diseases, respectively, via peptide presentation or via antigen non-specific control of immune response. Association studies are subjected to a number of …

MaleAgingmedia_common.quotation_subjectLongevityPopulationHuman leukocyte antigenBiologyBiochemistryEndocrinologyGeneticsHLA-DRHumansAlleleeducationMolecular BiologyAgedmedia_commonGenetic associationAged 80 and overGeneticseducation.field_of_studyHistocompatibility TestingHaplotypeLongevityHLA-DR AntigensCell BiologyHistocompatibilityItalyFemaleExperimental Gerontology
researchProduct

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myel…

2007

Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison. Between 1987 and 2004, 2287 pts were entered in these studies of whom 1032 pts (45%) without FAB M3 or t(15;17) were in CR1 after 2 cycles of chemotherapy, received consolidation treatment, and were younger than 55 years of age and therefore eligible for allogeneic hematopoietic stem cell transplantation (allo-SCT). An HLA-identical sibling donor was available for 326 pt…

MaleMyeloidTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationBiochemistryGastroenterologyRecurrenceRisk FactorsUNRELATED DONORSLiving DonorsMedicineTOTAL-BODYACUTE MYELOGENOUS LEUKEMIAHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyCOLONY-STIMULATING FACTORMiddle AgedChemotherapy regimenSurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureFemalePOSTREMISSION THERAPYAdultmedicine.medical_specialtyAcute myeloblastic leukemiaAdolescentImmunologymacromolecular substancesDisease-Free SurvivalMeta-Analysis as TopicInternal medicineotorhinolaryngologic diseasesHumansTransplantation HomologousSurvival rateRetrospective StudiesEUROPEAN GROUPbusiness.industryACUTE MYELOBLASTIC-LEUKEMIACell Biologymedicine.diseaseBONE-MARROW-TRANSPLANTATIONINTENSIVE CHEMOTHERAPYSurgeryTransplantationAML-10 TRIALbusinessFollow-Up StudiesBlood
researchProduct